Medicare reimbursement issues.
FDA regulations of biosimilars.
Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
Ensuring Access to Lower-Cost Medicines for Seniors Act.
S.4302 - Senator Marshall, the Biologics Market Transparency Act.
H.R.2679 - Pharmacy Benefits Manager Accountability Act.
H.R.1790 - Biologics Competition Act of 2023.
S.2305 - Biosimilar Red Tape Elimination Act.
Drug pricing legislation.
Labor, Health and Human Services issues.
Efforts surrounding user fees.
Duration: January 1, 2019
to
present
General Issues: Medicare/Medicaid , Health Issues , Medical/Disease Research/Clinical Labs , Pharmacy , Accounting
Spending: about $1,940,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
Related Foreign Entities:
Boehringer Ingelheim GmbH (55216 Ingelheim am Rhein, GER); contribution to lobbying: $0; ownership 100%; Merck KGaA (64293 Darmstadt, GER); contribution to lobbying: $0; ownership 100%; Samsung Bioepis (Incheon, KOR); contribution to lobbying: $0; ownership 100%; Novartis AG (Basel, SUI); contribution to lobbying: $0; ownership 100%; Teva Pharmaceutical Industries Ltd. (Petah Tikva, ISR); contribution to lobbying: $0; ownership 100%; Fresenius Kabi AG (61352 Bad Homburg vor der Hohe, GER); contribution to lobbying: $0; ownership 100%; Merck KGaA (64293 Darmstadt, GER); contribution to lobbying: $0; ownership 100%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Stuart Chapman Chief of Staff, Representative Carolyn McCarthy; Chief of Staff, Representative Zack Space; Press Secretary, Senator Jay Rockefeller; Press Secretary, Representative Barbara Lee
Alex DelPizzo Legislative Director/Legislative Asst, Rep. Ferguson; Staff Asst, House Transportation and Infrastructure Committee
Jessie Brairton Senior LA/LA: Cong L.Smith; LC,Asst: Senate Aging Comm
Thayer Roberts n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Thorn Run Partners lobbied for The Biosimilars Forum , earning $100,000. The report was filed on April 22.
Original Filing: 301571767.xml
Lobbying Issues
Medicare reimbursement issues.
FDA regulations of biosimilars.
Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
Ensuring Access to Lower-Cost Medicines for Seniors Act.
S.4302 - Senator Marshall, the Biologics Market Transparency Act.
H.R.2679 - Pharmacy Benefits Manager Accountability Act.
H.R.1790 - Biologics Competition Act of 2023.
S.2305 - Biosimilar Red Tape Elimination Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug pricing legislation.
Labor, Health and Human Services issues.
Efforts surrounding user fees.
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Thorn Run Partners lobbied for The Biosimilars Forum , earning $110,000. The report was filed on Jan. 22.
Original Filing: 301538212.xml
Lobbying Issues
Medicare reimbursement issues.
FDA regulations of biosimilars.
Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
Ensuring Access to Lower-Cost Medicines for Seniors Act.
S.4302 - Senator Marshall, the Biologics Market Transparency Act.
H.R.2679 - Pharmacy Benefits Manager Accountability Act.
H.R.1790 - Biologics Competition Act of 2023.
S.2305 - Biosimilar Red Tape Elimination Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug pricing legislation.
Labor, Health and Human Services issues.
Efforts surrounding user fees.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Thorn Run Partners lobbied for The Biosimilars Forum , earning $110,000. The report was filed on Oct. 20, 2023.
Original Filing: 301509599.xml
Lobbying Issues
Medicare reimbursement issues.
FDA regulations of biosimilars.
Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
Ensuring Access to Lower-Cost Medicines for Seniors Act.
S.4302 - Senator Marshall, the Biologics Market Transparency Act.
H.R.2679 - Pharmacy Benefits Manager Accountability Act.
H.R.1790 - Biologics Competition Act of 2023.
S.2305 - Biosimilar Red Tape Elimination Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug pricing legislation.
Labor, Health and Human Services issues.
Efforts surrounding user fees.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Thorn Run Partners lobbied for The Biosimilars Forum , earning $90,000. The report was filed on July 20, 2023.
Original Filing: 301485117.xml
Lobbying Issues
Medicare reimbursement issues.
FDA regulations of biosimilars.
Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
Ensuring Access to Lower-Cost Medicines for Seniors Act.
S.4302 - Senator Marshall, the Biologics Market Transparency Act.
H.R.2679 - Pharmacy Benefits Manager Accountability Act.
H.R.1790 - Biologics Competition Act of 2023.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug pricing legislation.
Labor, Health and Human Services issues.
Efforts surrounding user fees.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Thorn Run Partners lobbied for The Biosimilars Forum , earning $90,000. The report was filed on April 20, 2023.
Original Filing: 301462355.xml
Lobbying Issues
Medicare reimbursement issues.
FDA regulations of biosimilars.
Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug pricing legislation.
Labor, Health and Human Services issues.
Efforts surrounding user fees.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Thorn Run Partners lobbied for The Biosimilars Forum , earning $90,000. The report was filed on Jan. 20, 2023.
Original Filing: 301436331.xml
Lobbying Issues
Medicare reimbursement issues.
FDA regulations of biosimilars.
Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
H.R.2617 - Consolidated Appropriations Act, 2023, as it relates to the Departments of Labor, Health and Human Services, and Education, and
Related Agencies Appropriations Act, 2023.
H.R.2815 - BIOSIM Act.
H.R.2855 - Star Rating for Biosimilars Act.
H.R.2869/S.1427 - Increasing Access to Biosimilars Act of 2021.
H.R.5376 - Inflation Reduction Act of 2022
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug pricing legislation.
H.R.4502 - Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022.
H.R.2815 - BIOSIM Act.
H.R.2855 - Star Rating for Biosimilars Act.
H.R.2869/S.1427 - Increasing Access to Biosimilars Act of 2021.
H.R.5376 - Inflation Reduction Act of 2022.
Efforts surrounding user fees.
H.R.7006 - INSPECTIONS Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Thorn Run Partners lobbied for The Biosimilars Forum , earning $90,000. The report was filed on Oct. 21, 2022.
Original Filing: 301420255.xml
Lobbying Issues
Medicare reimbursement issues.
FDA regulations of biosimilars.
Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
H.R.4502 - Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2022.
H.R.2815 - BIOSIM Act.
H.R.2855 - Star Rating for Biosimilars Act.
H.R.2869 - Increasing Access to Biosimilars Act of 2021.
S.1427 - Increasing Access to Biosimilars Act of 2021.
H.R.5376 - Inflation Reduction Act of 2022
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug pricing legislation.
H.R.4502 - Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022.
H.R.2815 - BIOSIM Act.
H.R.2855 - Star Rating for Biosimilars Act.
H.R.2869 - Increasing Access to Biosimilars Act of 2021.
S.1427 - Increasing Access to Biosimilars Act of 2021.
H.R.5376 - Inflation Reduction Act of 2022.
Efforts surrounding user fees.
H.R.7006 - INSPECTIONS Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Thorn Run Partners lobbied for The Biosimilars Forum , earning $90,000. The report was filed on July 20, 2022.
Original Filing: 301393372.xml
Lobbying Issues
Medicare reimbursement issues. FDA regulations of biosimilars.
Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
H.R. 4502, Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2022
H.R. 2815, BIOSIM Act
H.R. 2855, Star Rating for Biosimilars Act.
H.R. 2869, Increasing Access to Biosimilars Act of 2021.
S. 1427, Increasing Access to Biosimilars Act of 2021.
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug pricing legislation.
H.R. 4502, Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
H.R. 4502, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022.
H.R. 2815, BIOSIM Act
H.R. 2855, Star Rating for Biosimilars Act.
H.R. 2869, Increasing Access to Biosimilars Act of 2021.
S. 1427, Increasing Access to Biosimilars Act of 2021.
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Efforts surrounding user fees.
H.R. 7006, the Improving the Nations Safe Pharmaceuticals and Excipients by Creating Tools for Inspecting and Overseeing Needed Supplies Act or the INSPECTIONS Act
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Thorn Run Partners lobbied for The Biosimilars Forum , earning $90,000. The report was filed on April 20, 2022.
Original Filing: 301369410.xml
Lobbying Issues
Medicare reimbursement issues. FDA regulations of biosimilars.
Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022
H.R. 2815, BIOSIM Act
H.R. 2855, Star Rating for Biosimilars Act.
H.R. 2869, Increasing Access to Biosimilars Act of 2021.
S. 1427, Increasing Access to Biosimilars Act of 2021.
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug pricing legislation.
Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022.
H.R. 2815, BIOSIM Act
H.R. 2855, Star Rating for Biosimilars Act.
H.R. 2869, Increasing Access to Biosimilars Act of 2021.
S. 1427, Increasing Access to Biosimilars Act of 2021.
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Efforts surrounding user fees.
H.R. 7006, the Improving the Nations Safe Pharmaceuticals and Excipients by Creating Tools for Inspecting and Overseeing Needed Supplies Act or the INSPECTIONS Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Thorn Run Partners lobbied for The Biosimilars Forum , earning $90,000. The report was filed on Jan. 19, 2022.
Original Filing: 301328568.xml
Lobbying Issues
Drug pricing legislation.
Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022.
H.R. 2815, BIOSIM Act
H.R. 2855, Star Rating for Biosimilars Act.
H.R. 2869, Increasing Access to Biosimilars Act of 2021.
S. 1427, Increasing Access to Biosimilars Act of 2021.
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare reimbursement issues. FDA regulations of biosimilars.
Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022
H.R. 2815, BIOSIM Act
H.R. 2855, Star Rating for Biosimilars Act.
H.R. 2869, Increasing Access to Biosimilars Act of 2021.
S. 1427, Increasing Access to Biosimilars Act of 2021.
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Thorn Run Partners lobbied for The Biosimilars Forum , earning $90,000. The report was filed on Oct. 20, 2021.
Original Filing: 301313462.xml
Lobbying Issues
Drug pricing legislation.
Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022.
H.R. 2815, BIOSIM Act
H.R. 2855, Star Rating for Biosimilars Act.
H.R. 2869, Increasing Access to Biosimilars Act of 2021.
S. 1427, Increasing Access to Biosimilars Act of 2021.
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare reimbursement issues. FDA regulations of biosimilars.
Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022
H.R. 2815, BIOSIM Act
H.R. 2855, Star Rating for Biosimilars Act.
H.R. 2869, Increasing Access to Biosimilars Act of 2021.
S. 1427, Increasing Access to Biosimilars Act of 2021.
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Thorn Run Partners lobbied for The Biosimilars Forum , earning $90,000. The report was filed on July 20, 2021.
Original Filing: 301289334.xml
Lobbying Issues
Drug pricing legislation.
Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
S. 164, Advancing Education on Biosimilars Act of 2021.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act
H.R. 2815, BIOSIM Act
H.R. 2855, Star Rating for Biosimilars Act.
H.R. 2868, Protecting Access to Affordable Medicines Act of 2021
H.R. 2869, Increasing Access to Biosimilars Act of 2021.
S. 1427, Increasing Access to Biosimilars Act of 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare reimbursement issues. FDA regulations of biosimilars.
Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
S. 164, Advancing Education on Biosimilars Act of 2021.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act
H.R. 2815, BIOSIM Act
H.R. 2855, Star Rating for Biosimilars Act.
H.R. 2868, Protecting Access to Affordable Medicines Act of 2021
H.R. 2869, Increasing Access to Biosimilars Act of 2021.
S. 1427, Increasing Access to Biosimilars Act of 2021.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Thorn Run Partners lobbied for The Biosimilars Forum , earning $90,000. The report was filed on April 20, 2021.
Original Filing: 301262396.xml
Lobbying Issues
Drug pricing legislation.
Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
S. 164, Advancing Education on Biosimilars Act of 2021.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare reimbursement issues. FDA regulations of biosimilars.
Issues related to Drug Pricing Reduction and increasing access to Biosimilars.
S. 164, Advancing Education on Biosimilars Act of 2021.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2022
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, Thorn Run Partners lobbied for The Biosimilars Forum , earning $90,000. The report was filed on Jan. 20, 2021.
Original Filing: 301241423.xml
Lobbying Issues
Medicare reimbursement issues. FDA regulations of biosimilars.
H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019.
H.R. 4455, BIOSIM Act.
H.R. 4629, Star Rating for Biosimilars Act.
S. 1895, Lower Health Care Costs Act.
S. 3466, ACCESS for Biosimilars Act of 2020.
H.R. 6179, Increasing Access to Biosimilars Act of 2020.
S. 4134, A bill to establish a demonstration project to increase access to biosimilar products under the Medicare program.
H.R. 133, Consolidating Appropriations Act, 2021.
H.R. 925, HEROES Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug pricing legislation.
S. 2543, Prescription Drug Pricing Reduction Act of 2019.
H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019.
H.R. 4455, BIOSIM Act.
H.R. 4629, Star Rating for Biosimilars Act.
S. 1895, Lower Health Care Costs Act.
S. 3466, ACCESS for Biosimilars Act of 2020.
H.R. 6179, Increasing Access to Biosimilars Act of 2020.
S. 4134, A bill to establish a demonstration project to increase access to biosimilar products under the Medicare program.
H.R. 133, Consolidating Appropriations Act, 2021.
H.R. 925, HEROES Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Thorn Run Partners lobbied for The Biosimilars Forum , earning $90,000. The report was filed on Oct. 20, 2020.
Original Filing: 301220841.xml
Lobbying Issues
Medicare reimbursement issues. FDA regulations of biosimilars.
H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019.
H.R. 4455, BIOSIM Act.
H.R. 4629, Star Rating for Biosimilars Act.
S. 1895, Lower Health Care Costs Act.
S. 3466, ACCESS for Biosimilars Act of 2020.
H.R. 6179, Increasing Access to Biosimilars Act of 2020.
S. 4134, A bill to establish a demonstration project to increase access to biosimilar products under the Medicare program.
The Cares Act (P.L. 116-136).
H.R. 925, HEROES Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug pricing legislation.
S. 2543, Prescription Drug Pricing Reduction Act of 2019.
H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019.
H.R. 4455, BIOSIM Act.
H.R. 4629, Star Rating for Biosimilars Act.
S. 1895, Lower Health Care Costs Act.
S. 3466, ACCESS for Biosimilars Act of 2020.
H.R. 6179, Increasing Access to Biosimilars Act of 2020.
S. 4134, A bill to establish a demonstration project to increase access to biosimilar products under the Medicare program.
The Cares Act (P.L. 116-136).
H.R. 925, HEROES Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Thorn Run Partners lobbied for The Biosimilars Forum , earning $90,000. The report was filed on July 20, 2020.
Original Filing: 301196551.xml
Lobbying Issues
Medicare reimbursement issues. FDA regulations of biosimilars.
H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019.
H.R. 4455, BIOSIM Act.
H.R. 4629, Star Rating for Biosimilars Act.
S. 1895, Lower Health Care Costs Act.
S. 3466, ACCESS for Biosimilars Act of 2020.
H.R. 6179, Increasing Access to Biosimilars Act of 2020.
S. 4134, A bill to establish a demonstration project to increase access to biosimilar products under the Medicare program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug pricing legislation.
S. 2543, Prescription Drug Pricing Reduction Act of 2019.
H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019.
H.R. 4455, BIOSIM Act.
H.R. 4629, Star Rating for Biosimilars Act.
S. 1895, Lower Health Care Costs Act.
S. 3466, ACCESS for Biosimilars Act of 2020.
H.R. 6179, Increasing Access to Biosimilars Act of 2020.
S. 4134, A bill to establish a demonstration project to increase access to biosimilar products under the Medicare program.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Thorn Run Partners lobbied for The Biosimilars Forum , earning $90,000. The report was filed on April 20, 2020.
Original Filing: 301176273.xml
Lobbying Issues
Medicare reimbursement issues. FDA regulations of biosimilars.
H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019.
H.R. 4455, BIOSIM Act.
H.R. 4629, Star Rating for Biosimilars Act.
S. 1895, Lower Health Care Costs Act.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
S. 3466, ACCESS for Biosimilars Act of 2020.
H.R. 6179, Increasing Access to Biosimilars Act of 2020.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug pricing legislation.
H.R. 1520, Purple Book Continuity Act of 2019.
S. 2543, Prescription Drug Pricing Reduction Act of 2019.
H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019.
H.R. 4455, BIOSIM Act.
H.R. 4629, Star Rating for Biosimilars Act.
S. 1895, Lower Health Care Costs Act.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
S. 3466, ACCESS for Biosimilars Act of 2020.
H.R. 6179, Increasing Access to Biosimilars Act of 2020.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Thorn Run Partners lobbied for The Biosimilars Forum , earning $90,000. The report was filed on Jan. 21, 2020.
Original Filing: 301128820.xml
Lobbying Issues
Medicare reimbursement issues. FDA regulations of biosimilars.
H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019.
H.R. 4455, BIOSIM Act.
H.R. 4629, Star Rating for Biosimilars Act.
S. 1895, Lower Health Care Costs Act.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug pricing legislation.
H.R. 1520, Purple Book Continuity Act of 2019.
S. 2543, Prescription Drug Pricing Reduction Act of 2019.
H.R. 4597, Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019.
H.R. 4455, BIOSIM Act.
H.R. 4629, Star Rating for Biosimilars Act.
S. 1895, Lower Health Care Costs Act.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Thorn Run Partners lobbied for The Biosimilars Forum , earning $90,000. The report was filed on Oct. 16, 2019.
Original Filing: 301066376.xml
Lobbying Issues
Medicare reimbursement issues. FDA regulations of biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug pricing legislation.
H.R. 1520, Purple Book Continuity Act of 2019.
S. 2543, Prescription Drug Pricing Reduction Act of 2019.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Thorn Run Partners lobbied for The Biosimilars Forum , earning $90,000. The report was filed on July 18, 2019.
Original Filing: 301048540.xml
Lobbying Issues
Medicare reimbursement issues. FDA regulations of biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug pricing legislation. HR 1520, Purple Book Continuity Act of 2019.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Thorn Run Partners lobbied for The Biosimilars Forum , earning $90,000. The report was filed on April 22, 2019.
Original Filing: 301037583.xml
Lobbying Issues
Medicare reimbursement issues. FDA regulations of biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Drug pricing legislation. HR 1520, Purple Book Continuity Act of 2019.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
Thorn Run Partners filed a lobbying registration on March 7, 2019 to represent The Biosimilars Forum, effective Jan. 1, 2019.
Original Filing: 301021241.xml
Issue(s) they said they’d lobby about: Medicare reimbursement issues; FDA regulations of biosimilars. .
1st Quarter, 2019
Thorn Run Partners filed a lobbying registration on Feb. 14, 2019 to represent The Biosimilars Forum, effective Jan. 1, 2019.
Original Filing: 301020373.xml
Issue(s) they said they’d lobby about: Medicare reimbursement issues; FDA regulations of biosimilars. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...